GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Precision BioSciences
Precision BioSciences is a biotech company pioneering gene editing with its ARCUS platform. Its stock price is a venture bet that its technology will prove more precise and safer than CRISPR.
Share prices of companies in the market segment - Dna
Precision BioSciences is a biotech company using its ARCUS gene editing platform to develop cell and gene therapies. We've categorized it as a "DNA" company, and the chart below shows how the market views the prospects for this breakthrough in genetic medicine.
Broad Market Index - GURU.Markets
Precision BioSciences is a biotech company using its ARCUS gene-editing platform to develop cell and gene therapies. It is a component of the GURU.Markets index. The chart below represents the market. See how this stock compares to the biotech sector.
Change in the price of a company, segment, and market as a whole per day
DTIL - Daily change in the company's share price Precision BioSciences
For Precision BioSciences, Inc., a gene editing company, daily volatility reflects sensitivity to scientific data. This metric is an important element in formulas that assess the risks and potential of companies in this innovative field.
Daily change in the price of a set of shares in a market segment - Dna
Precision BioSciences, Inc. is a gene editing company. This chart highlights the sector's high volatility. Comparing it to DTIL, with its unique platform, helps to assess it as an innovative but risky player.
Daily change in the price of a broad market stock, index - GURU.Markets
Precision BioSciences is a pioneer in the field of genome editing, developing treatments based on this technology. The company's shares are a bet on a scientific revolution. Their extreme data-driven volatility is part of the dynamic of the innovation sector.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Precision BioSciences
For Precision BioSciences, the year-over-year trend is a story about its unique gene-editing platform, ARCUS. Its market cap change over the next 12 months depends entirely on clinical trial data from its "off-the-shelf" CAR-T therapy and in vivo gene therapy programs. Success could confirm the advantages of its technology over CRISPR.
Annual dynamics of market capitalization of the market segment - Dna
Precision BioSciences, Inc. is a biotechnology company pioneering the development of next-generation gene editing technologies (ARCUS). Its stock performance is entirely dependent on clinical trial results. The chart reflects the enormous potential and high risks of this cutting-edge field.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Precision BioSciences, a pioneer in genome editing, is a bet on the technology of the future. Its stock price is completely unrelated to the economy. Its chart reflects the hopes, risks, and scientific breakthroughs in one of the most advanced fields of medicine. It's a long-term bet on technology.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Precision BioSciences
Precision BioSciences is a gene editing company using its ARCUS platform. Its monthly performance is driven by progress in its clinical and preclinical programs. News of partnerships with major pharmaceutical companies is a key driver of its value.
Monthly dynamics of market capitalization of the market segment - Dna
Gene editing is a revolutionary technology in medicine, but it carries enormous scientific and ethical risks. The dynamics of this biotech sector, shown in the chart, reflect its speculative nature. Companies like Precision BioSciences are at the forefront of this field.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Precision BioSciences, a company developing gene editing technologies, is a high-risk biotech. Its shares move solely on news of scientific breakthroughs and partnerships, completely ignoring overall market trends.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Precision BioSciences
Shares of Precision BioSciences, a gene editing company, are experiencing high volatility on a weekly basis. News about the progress of its cell therapy clinical trials and advances in in vivo gene editing are causing sharp price movements.
Weekly dynamics of market capitalization of the market segment - Dna
Precision BioSciences shares, like those of the entire gene editing sector, are moving against a backdrop of scientific breakthroughs and investor expectations. Regulatory news is creating extreme volatility for everyone. The chart will show whether the company is leading the hype.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Precision BioSciences shares, like those of the entire gene editing sector, are moving against a backdrop of scientific breakthroughs and investor expectations. Regulatory news is creating extreme volatility for everyone. The chart will show whether the company is leading the hype.
Market capitalization of the company, segment and market as a whole
DTIL - Market capitalization of the company Precision BioSciences
The Precision BioSciences market capitalization chart is a financial valuation of a biotech company working in gene editing using its ARCUS platform. It reflects both the technology's potential and its strategic shift toward in vivo therapeutics. Its dynamics are a history of adaptation and the search for the most promising applications for its unique science.
DTIL - Share of the company's market capitalization Precision BioSciences within the market segment - Dna
Precision BioSciences is a biotech company using its proprietary gene-editing platform, ARCUS, to develop cell and gene therapies. Its market share reflects both the potential of its unique technology and the intense competition in the field. The chart below is an indicator of the market's faith in its science.
Market capitalization of the market segment - Dna
Precision BioSciences is a leading gene editing company using its ARCUS platform. The chart below shows the overall market capitalization of the DNA analysis sector. Its dynamics reflect the hopes for the development of drugs capable of "correcting" genes. Precision is at the forefront of this science.
Market capitalization of all companies included in a broad market index - GURU.Markets
Gene editing, as seen in the graph, is one of the most cutting-edge technologies. Precision BioSciences is developing its own gene editing platform, called ARCUS. Its capitalization is a risky bet that its technology will prove safe and effective for treating genetic diseases.
Book value capitalization of the company, segment and market as a whole
DTIL - Book value capitalization of the company Precision BioSciences
Precision BioSciences's schedule is capital for precision gene editing. The company's R&D-stage book value consists of financial reserves. These assets are used to develop the ARCUS platform, which enables highly precise DNA modifications for the creation of cell and gene therapies.
DTIL - Share of the company's book capitalization Precision BioSciences within the market segment - Dna
Precision BioSciences, a gene editing company, has cutting-edge R&D and manufacturing capabilities. Its stake in the sector reflects its ownership of laboratories and equipment for developing its unique ARCUS editing platform.
Market segment balance sheet capitalization - Dna
Precision BioSciences is a genome editing company, making its model intellectually rather than capital-intensive. The company's value lies in its ARCUS platform, not its manufacturing facilities. Compared to the biotech sector as a whole, its "light" balance sheet is typical of companies at the forefront of science.
Book value of all companies included in the broad market index - GURU.Markets
Precision BioSciences' assets are not drugs, but rather a unique gene-editing platform, ARCUS, which enables precise cuts in DNA. The company's balance sheet reflects the value of this cutting-edge technology. The chart shows how much capital is invested in developing safer and more effective genetic engineering methods.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Precision BioSciences
Precision BioSciences is a company working in the field of genome editing. Its market value is derived from the valuation of its unique ARCUS platform. Investors are betting on its potential to develop gene and cell therapies, an intangible asset far removed from its book value.
Market to book capitalization ratio in a market segment - Dna
Precision BioSciences is a genome editing company. Its value lies in its unique ARCUS technology. This chart illustrates a classic biotech story: a market valuation based on faith in breakthrough technology bears no relation to the value of its lab equipment.
Market to book capitalization ratio for the market as a whole
Precision BioSciences is a biotech company specializing in gene editing. Its market cap is based almost entirely on the potential of its scientific platform. This chart clearly demonstrates the extreme premium the market pays for breakthrough scientific ideas that have the potential to transform medicine, compared to the market average.
Debts of the company, segment and market as a whole
DTIL - Company debts Precision BioSciences
Precision BioSciences is a gene editing company. Developing such a cutting-edge therapeutic platform requires significant and long-term investment. This chart shows how the company is raising capital to fund its preclinical and clinical programs in oncology and rare diseases.
Market segment debts - Dna
Precision BioSciences is a biotech company specializing in gene editing, a cutting-edge but extremely capital-intensive field. This chart shows how the company funds its unique ARCUS platform, which is almost exclusively through equity and strategic partnerships due to the high risk and long-term nature of the research.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Precision BioSciences
Precision BioSciences, a company working in the field of genome editing, is at the forefront of science. This chart shows the extent to which its expensive research is financed by debt. This is one of the riskiest areas of investment, where high debt is a bet on a technological breakthrough that may never materialize.
Market segment debt to market segment book capitalization - Dna
Precision BioSciences is a pioneer in genome editing, using its ARCUS platform to develop cell and gene therapies. This chart compares the debt raised for this breakthrough, yet risky, research to the overall market capitalization of the DNA therapeutics sector. It reflects the enormous financial stakes being placed on future technologies.
Debt to book value of all companies in the market
Precision BioSciences is a biotech company working in gene editing, a cutting-edge but highly capital-intensive field. The chart shows how the company finances its expensive research. Its debt load, compared to other players in the gene therapy sector, reflects investors' confidence in its platform and the associated risks.
P/E of the company, segment and market as a whole
P/E - Precision BioSciences
This chart for Precision BioSciences, a gene editing company, evaluates its unique ARCUS technology. The stock price relative to potential earnings reflects investor confidence in the precision and safety of its approach. The price movement reflects the response to preclinical and clinical trial data.
P/E of the market segment - Dna
This chart reflects the average valuation for the speculative gene therapy sector—a benchmark for Precision BioSciences. The entire sector is valued based on expectations for future breakthroughs. For investors, this serves as a benchmark, indicating the overall level of faith in this technology. Against this backdrop, expectations for the ARCUS platform can be gauged.
P/E of the market as a whole
Precision BioSciences is a gene editing company that uses its proprietary ARCUS technology to develop cell and gene therapies. It is one of the key technologies in modern biotechnology. This chart shows the market's risk appetite. It allows us to understand how investors view the potential of the ARCUS platform compared to the better-known CRISPR platform and its chances of success.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Precision BioSciences
Precision BioSciences is a biotech company that uses its proprietary gene-editing technology, ARCUS, to develop cell and gene therapies. This chart reflects analysts' expectations for its unique scientific platform. It reflects market confidence that ARCUS may be a more precise and safer tool than CRISPR.
%20P%2FE%20Precision%20BioSciences&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Precision-BioSciences&v=1772553307828 "Chart of the company's future (projected) P/E Precision BioSciences")
Future (projected) P/E of the market segment - Dna
Precision BioSciences is a biotech company using its proprietary ARCUS gene-editing platform to develop cell and gene therapies. This chart shows how its profitability expectations compare to the biotech sector. It reflects how the market views its unique genome-editing technology and its potential to treat cancer and genetic diseases.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Dna&v=1772553307932 "Future (projected) P/E graph of the market segment - Dna")
Future (projected) P/E of the market as a whole
Precision BioSciences is a biotech company developing gene therapy based on its ARCUS genome editing platform. This chart shows the company's overall risk appetite. DTIL's success depends on clinical trial results. A positive market environment helps with funding, but cannot replace a scientific breakthrough.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772553307980 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Precision BioSciences
Precision BioSciences is a biotechnology company developing therapeutics based on its proprietary gene editing platform, ARCUS. This chart shows the financial impact of advanced genetic technologies. Current results reflect investments in the development of both cell therapies and in vivo gene editing methods.
Profit of companies in the market segment - Dna
Precision BioSciences is a biotechnology company that uses its proprietary gene editing platform, ARCUS, to develop cell and gene therapies. The company's technology enables precise DNA editing. This chart shows the financial pulse of the genetic engineering sector, reflecting both the enormous potential and the high risks associated with this cutting-edge technology.
Overall market profit
Precision BioSciences is a biotechnology company developing gene therapy. Its future is determined by scientific progress. Economic cycles do not affect the need for treatments for genetic diseases. However, as with any biotech company, the availability of capital for expensive research depends on the overall state of the financial markets.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Precision BioSciences
Precision BioSciences is a biotechnology company pioneering gene editing with its ARCUS platform. This timeline represents a long-term model based on analysts' belief that this unique technology could form the basis of new treatments for genetic diseases.
%20profit%20of%20the%20company%20Precision%20BioSciences&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Precision-BioSciences&v=1772553308607 "Graph of future (projected) profit of the company Precision BioSciences")
Future (predicted) profit of companies in the market segment - Dna
Precision BioSciences is a pioneer in gene editing using its unique ARCUS platform. This chart shows forecasts for the biotech sector. The company's future profitability depends on the success of both its in vivo therapeutic programs and its developments in cell therapy, where the precision and safety of genome editing are key.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Dna&v=1772553308711 "Graph of future (predicted) profits of companies in a market segment - Dna")
Future (predicted) profit of the market as a whole
Precision BioSciences is developing gene therapy. This cutting-edge field of science requires massive, long-term investment. This graph, which displays corporate profit forecasts, is an indicator of the overall health of financial markets and investor risk appetite, which is critical for funding such capital-intensive biotech companies.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772553308895 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Precision BioSciences
Precision BioSciences is a biotech company using its ARCUS gene editing platform to develop cell and gene therapies. This chart shows that the company's valuation is based on its scientific potential, reflecting investor expectations that its technology will prove more precise and safer than CRISPR.
P/S market segment - Dna
Precision BioSciences is a biotech company that uses its proprietary ARCUS gene editing platform to develop cell and gene therapies. ARCUS is known for its high precision. This chart reflects the average biotech valuation, helping to understand the market premium placed on Precision's unique and potentially safer gene editing technology.
P/S of the market as a whole
Precision BioSciences is a biotech company developing therapies based on its proprietary gene editing platform, ARCUS. This is at the forefront of medicine. This average market revenue valuation clearly demonstrates that the company's valuation is based not on current sales, but on the potential of its unique technology.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Precision BioSciences
Precision BioSciences is a genome editing company using its unique ARCUS platform to develop cell and gene therapies. This chart reflects investors' confidence in this technology. The valuation is based on potential future revenue from its therapeutic programs and partnerships with other pharmaceutical companies.
%20P%2FS%20Precision%20BioSciences&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Precision-BioSciences&v=1772553309294 "The graph of the company's future (projected) P/S Precision BioSciences")
Future (projected) P/S of the market segment - Dna
Precision BioSciences is a biotech company developing therapeutics based on its proprietary gene-editing platform, ARCUS. This chart compares the company's future revenue expectations with its industry. It reflects investor confidence in the uniqueness and safety of its technology compared to CRISPR.
%20P%2FS%20market%20segment%20graph%20-%20Dna&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Dna&v=1772553309374 "Future (projected) P/S market segment graph - Dna")
Future (projected) P/S of the market as a whole
Precision BioSciences is a biotech company developing therapies based on its proprietary gene editing platform, ARCUS. This schedule reflects confidence in future growth, and Precision BioSciences is working at the forefront of science. The success of its technology could lead to new treatments for genetic diseases and cancer.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772553309378 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Precision BioSciences
Precision BioSciences is a biotech company specializing in gene editing using its ARCUS platform. Its revenue, shown in this chart, is generated not from sales but from upfront and milestone payments from major pharmaceutical partners through strategic alliances.
Sales of companies in the market segment - Dna
Precision BioSciences is a biotechnology company pioneering gene editing with its ARCUS platform. They develop both cell therapies and in vivo treatments for genetic diseases. This graph reflects the revolutionary potential of genetic engineering, where such technologies can transform medicine.
Overall market sales
Precision BioSciences is a biotechnology company developing genome editing methods. Its future depends on scientific breakthroughs and capital raising. The growth in total economic revenue, reflected in this chart, creates a favorable investment climate. This allows companies like Precision BioSciences to fund their long-term and capital-intensive R&D programs.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Precision BioSciences
Precision BioSciences is a biotechnology company using its proprietary gene-editing platform, ARCUS, to develop cell and gene therapies. This graph reflects analyst expectations for the success of its clinical trials and the potential of its unique genome-editing technology.
%20sales%20of%20the%20company%20Precision%20BioSciences&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Precision-BioSciences&v=1772553309717 "Schedule of future (projected) sales of the company Precision BioSciences")
Future (projected) sales of companies in the market segment - Dna
Precision BioSciences is a biotechnology company using its unique ARCUS gene editing platform to develop cell and gene therapies. This chart shows forecasts for the DNA technology sector. It reflects the enormous potential and scientific interest in genome editing technologies, in which Precision is a key player.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Dna&v=1772553309805 "Schedule of future (projected) sales of companies in the market segment - Dna")
Future (projected) sales of the market as a whole
Precision BioSciences, a gene editing company, sees this chart as an indicator of investor appetite for breakthrough technologies. The optimistic economic forecasts reflected here create a favorable environment for funding long-term, capital-intensive research aimed at developing new treatments.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772553309922 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Precision BioSciences
Precision BioSciences is a biotechnology company working with cutting-edge gene editing technology called ARCUS. Being at the forefront of science, the company incurs significant research expenditures. This chart illustrates the cost of innovation, showing the amount of capital invested in developing a platform that has the potential to transform the treatment of many diseases.
Market segment marginality - Dna
Precision BioSciences is a biotech company working in gene editing using its ARCUS platform. Efficiency in this cutting-edge field means the ability to rapidly develop and test new gene therapies while managing enormous R&D costs. The chart below shows how their operating model compares to other gene editing companies.
Market marginality as a whole
Precision BioSciences is a biotech company developing gene therapy based on its ARCUS genome editing platform. This chart shows today's profitability, while Precision Bio is working on the medicine of the future. Their financial history reflects investments in unique technology with potential for widespread application.
Employees in the company, segment and market as a whole
Number of employees in the company Precision BioSciences
Precision BioSciences is a company developing genome editing using its ARCUS platform. Its team, visible in this graph, consists of leading scientists in this cutting-edge field. The size of its staff reflects its investment in the development of both therapeutic and agricultural products.
Share of the company's employees Precision BioSciences within the market segment - Dna
Precision BioSciences is a leading company in the field of genome editing using its unique ARCUS platform. This chart shows the percentage of the world's most elite scientists in genetic engineering that Precision attracts. This is a direct indicator of its scientific leadership and the potential of its technology to create breakthrough cell and gene therapies.
Number of employees in the market segment - Dna
Precision BioSciences is a biotechnology company using its ARCUS gene editing platform. Its main asset is its team of scientists. This chart shows how the company is investing in its unique technology. The staffing dynamics reflect the company's activity in developing both its own therapeutic programs and partner projects.
Number of employees in the market as a whole
Precision BioSciences is a genome editing company. This is at the cutting edge of science, and its development depends on technological breakthroughs. This graph reflects the current job market, but Precision BioSciences is hiring exceptional specialists to create technologies that will transform medicine and the economy of the future.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Precision BioSciences (DTIL)
Precision BioSciences is a genome editing company. Its market capitalization reflects the market's valuation of its unique and potentially revolutionary technology. The very high value on this chart is typical for biotech, where intellectual property is the primary asset.
%20of%20the%20company%20Precision%20BioSciences%20(DTIL)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Precision-BioSciences-DTIL&v=1772553310427 "Chart of market capitalization per employee (in thousands of dollars) of the company Precision BioSciences (DTIL)")
Market capitalization per employee (in thousands of dollars) in the market segment - Dna
Precision BioSciences is a biotechnology company using its ARCUS gene editing platform to develop cell and gene therapies. The company's value lies in its unique and precise technology. This chart shows the premium investors are willing to pay for this cutting-edge science per scientist employed by the company.
%20by%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Dna&v=1772553310536 "Market capitalization per employee (in thousands of dollars) by market segment - Dna")
Market capitalization per employee (in thousands of dollars) for the overall market
Precision BioSciences is a biotech company developing therapies based on its ARCUS gene editing platform. This is cutting-edge research. The chart demonstrates the enormous value the market places on a small team of scientists, as their technology can enable precise gene editing to treat diseases.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772553310684 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Precision BioSciences (DTIL)
Precision BioSciences is a biotech company developing a gene editing platform (ARCUS) for cell therapy and gene correction. This is pure R&D. This graph will be negative, reflecting the amount of research investment per scientist. This is a bet on their unique genome editing technology.
%20Chart%20Precision%20BioSciences%20(DTIL)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Precision-BioSciences-DTIL&v=1772553310816 "Company Profit Per Employee (in thousands of dollars) Chart Precision BioSciences (DTIL)")
Profit per employee (in thousands of dollars) in the market segment - Dna
Precision BioSciences (DTIL) is a biotech company specializing in gene editing using its ARCUS platform. They use it to develop both cell therapies and gene correction. This chart reflects R&D efficiency: how successfully the team of scientists utilizes capital to advance their complex and expensive platform.
%20in%20the%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Dna&v=1772553310895 "Chart of profit per employee (in thousands of dollars) in the market segment - Dna")
Profit per employee (in thousands of dollars) for the market as a whole
Precision BioSciences is a biotech company working in gene editing (ARCU) to create cell and gene therapies. It's at the absolute cutting edge of science. This graph shows significant losses per employee. The company is investing hundreds of millions in a world-class team of scientists to create a platform that could transform medicine.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772553310976 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Precision BioSciences (DTIL)
Precision BioSciences is a biotech company developing gene editing methods for cell and gene therapies. During the research phase, this graph is an indicator of future potential. Revenue per employee, if any, typically comes from partnerships and signals progress in drug development.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Precision-BioSciences-DTIL&v=1772553311062 "Sales chart per company employee Precision BioSciences (DTIL)")
Sales per employee in the market segment - Dna
Precision BioSciences is a genetic engineering company that uses its ARCUS genome editing platform (as opposed to CRISPR). This chart shows the average revenue per employee in the sector. It serves as a benchmark, demonstrating the level of productivity required in this cutting-edge but capital-intensive field to achieve commercial success.
Sales per employee for the market as a whole
Precision BioSciences (DTIL) is a biotechnology company developing gene therapy (in vivo) and cell therapy (CAR-T) using its unique gene editing platform, ARCUS. It is an R&D company. This chart shows the current (minimum) partnership revenue per scientist.
Short shares by company, segment and market as a whole
Shares shorted by company Precision BioSciences (DTIL)
Precision BioSciences is a biotech company developing gene editing technology (ARCUS) for cell therapies and gene editing. This is a highly competitive field. The chart shows the number of investors betting that ARCUS technology will be inferior to CRISPR or that the company will fail to successfully commercialize its developments.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Precision-BioSciences-DTIL&v=1772553311137 "Short Shares Chart for the Company Precision BioSciences (DTIL)")
Shares shorted by market segment - Dna
Precision BioSciences is a pioneer in gene editing with its unique ARCUS technology. This chart measures the overall skepticism in the sector. Its rise indicates that investors are betting heavily against the entire gene therapy industry, fearing safety or delivery issues that are holding the entire industry back.
Shares shorted by the overall market
Precision BioSciences is working in the revolutionary field of genome editing. Their ARCUS platform is a technology with enormous potential, but also enormous risks. This chart reflects the general fear in the market. When investors are afraid, they are unwilling to bet on technologies that could change the world in 10 years. They are selling off DTIL shares, fearing the long road to profitability.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Precision BioSciences (DTIL)
Precision BioSciences uses its ARCUS gene-editing platform to develop cell and gene therapies. It's a high-tech biotech with significant risks and potential. This indicator measures the speed of price changes, reflecting "overheating" (above 70) on news of research breakthroughs or "oversold" (below 30) on development delays.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Precision-BioSciences-DTIL&v=1772553311298 "RSI 14 indicator chart for the company's stock Precision BioSciences (DTIL)")
RSI 14 Market Segment - Dna
Precision Bio (DTIL) is "GMO" 2.0 (like Cibus). They're a *biotech* that uses *"gene editing"* (*ARCUS*, *not* CRISPR) to *create* cell therapy (CAR-T). The "Dna" (biotech/gene therapy) sector thrives on news. RSI\_14\_Seg shows the "temperature" of the *entire* segment. It's vital to understand: is DTIL's growth due to their R&D, or is *the whole* biotech "overheated"?
RSI 14 for the overall market
Precision BioSciences (DTIL) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria offers the potential to easily raise hundreds of millions of dollars for research. Market panic risks running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast DTIL (Precision BioSciences)
Precision BioSciences (DTIL) is a biotech company developing ARCUUS genome editing technology (an alternative to CRISPR) for gene and cell therapy. This chart shows the average target price. It reflects analysts' speculative valuation of this unique platform and its R&D portfolio.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-DTIL-Precision-BioSciences&v=1772553311757 "A chart showing analyst consensus forecasts for the expected stock price. DTIL (Precision BioSciences)")
The difference between the consensus estimate and the actual stock price DTIL (Precision BioSciences)
Precision BioSciences (DTIL) is one of the first gene editing companies (ARCUS, "scissors") to pivot and now focus on in vivo therapies. This chart is a barometer of their R&D. It measures the gap between the price and the consensus target, reflecting the high potential analysts see in their new, focused strategy.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-DTIL-Precision-BioSciences&v=1772553311813 "A chart showing the difference between the consensus forecast and the actual stock price. DTIL (Precision BioSciences)")
Analyst consensus forecast for stock prices by market segment - Dna
Precision BioSciences is a biotech company pioneering gene editing (ARCUS), which it uses to develop cell therapies (CAR-T) and gene therapy (in vivo). This chart shows general expectations for the DNA technology sector. It reflects whether experts believe this R&D platform will be commercially successful.
Analysts' consensus forecast for the overall market share price
Precision Bio is a clinical-stage gene editing company. It's a risky R&D venture. This chart, which measures the market's overall risk appetite, is crucial. When optimism prevails, investors are willing to fund capital-intensive, breakthrough R&D projects. When pessimism rises, funding for companies like DTIL becomes scarce.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Precision BioSciences
Precision BioSciences is a pioneer in the field of genome editing. Their unique technology is not CRISPR, but their proprietary ARCUS engine, which they use to create universal (allogeneic) CAR-T cells for cancer treatment. This chart is a clear indicator of faith in their R&D. Its dynamics represent a speculative market assessment of their unique (non-CRISPR) scientific platform.
AKIMA Market Segment Index - Dna
Precision BioSciences (DTIL) is a biotechnology company using its proprietary ARCUS gene editing platform to develop cell and gene therapies, including allogeneic CAR-T. The chart shows the segment average. It helps investors assess how the risks and potential of ARCUS's unique technology compare to the average in the gene editing sector.
The AKIM Index for the overall market
Precision BioSciences is a genome editing company using the ARCUS platform to create in vivo therapies. This chart, which reflects the market average, is an indicator of risk appetite. It shows the macro backdrop, which is critical for funding this unique technology platform.
